Parisi, Federico
Corniani, Giulia
Bonato, Paolo
Balkwill, David
Acuna, Patrick
Go, Criscely
Sharma, Nutan
Stephen, Christopher D.
Funding for this research was provided by:
National Institutes of Health (P01NS087997, 1K23NS118045-01A1)
Article History
Received: 7 November 2023
Accepted: 3 June 2024
First Online: 9 June 2024
Competing interests
: Dr. Parisi reports no relevant disclosures. Dr. Corniani reports no relevant disclosures. Dr. Bonato has received grant support from the American Heart Association, the Department of Defense, the Michael J Fox Foundation, the National Institutes of Health (NIH), the National Science Foundation (NSF), and the Peabody Foundation including sub-awards on NIH and NSF SBIR grants from Barrett Technology (Newton MA), BioSensics (Watertown MA) and Veristride (Salt Lake City UT). He has also received grant support from Emerge Diagnostics (Carlsbad CA), MC10 (Lexington MA), Mitsui Chemicals (Tokyo Japan), Pfizer (New York City NY), Shimmer Research (Dublin Ireland), and SynPhNe (Singapore). He has served on the Advisory Board of SwanBio (Boston MA). Dr. Bonato serves in an advisory uncompensated role the Michael J Fox Foundation, the NIH-funded New England Pediatric Device Consortium, and the Walking Tall-PD clinical trial carried out by Neuroscience Research Australia. He also serves in an uncompensated role on the Scientific Advisory Boards of ABLE Human Motion (Barcelona, Spain), FormSense (San Diego CA, USA), Hocoma AG (Zurich, Switzerland), and Trexo (Toronto, Canada). Dr. Acuna reports no relevant disclosures. Dr. Go reports no relevant disclosures. Dr. Sharma receives support from Wiley Publishing for her role as editor-in-chief of Brain and Behavior. has received grant support from the Department of Defense and the National Institutes of Health (NIH). Dr. Stephen has received financial support from Encora Therapeutics, SwanBio Therapeutics, Sanofi-Genzyme, Biogen and Biohaven for the conduct of clinical trials. He has received honoraria from the Movement Disorders Society, American Academy of Neurology and from Oakstone CME. Dr. Stephen’s institution has received research funding from Sanofi-Genzyme for a study of video oculography in late-onset GM2 gangliosidosis.